In Washington, biotech's China hawks are winning the conversation

June 5, 2026 02:37 PM EDT ChinaPharma In Wash­ing­ton, biotech's Chi­na hawks are win­ning the con­ver­sa­tion Max Bayer Senior Reporter Bio­phar­ma in­dus­try lob­by groups work­ing to keep the pipeline open for plen­ti­ful, low­er-cost drugs com­ing from Chi­na have awak­ened to the fact that they face … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER